107 related articles for article (PubMed ID: 11170239)
1. Analysis for loss of heterozygosity (LOH) of p53 allele in tumors derived from p53+/- and CD-1 mice following repeated subcutaneous injections of solutions containing antioxidants.
Youssef AF; Borellini F; Jacobson-Kram D; Fort FL
Environ Mol Mutagen; 2001; 37(1):27-30. PubMed ID: 11170239
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
[TBL] [Abstract][Full Text] [Related]
3. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
Hulla JE; French JE; Dunnick JK
Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
[TBL] [Abstract][Full Text] [Related]
5. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
6. Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53+/- mice.
Vaslet CA; Messier NJ; Kane AB
Toxicol Sci; 2002 Aug; 68(2):331-8. PubMed ID: 12151629
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
[TBL] [Abstract][Full Text] [Related]
8. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
[TBL] [Abstract][Full Text] [Related]
9. Sarcoma at the injection site of gold sodium thiomalate.
Payne BJ
Vet Pathol; 1978 Aug; 15 Suppl 5():39-50. PubMed ID: 104420
[No Abstract] [Full Text] [Related]
10. Motif-primed polymerase chain reaction-based allelotype of sarcomas induced by 3-methylcholanthrene in interspecific hybrid mice.
Dudley ME; Sundberg JP; Roopenian DC
Oncogene; 1995 Aug; 11(3):517-24. PubMed ID: 7630636
[TBL] [Abstract][Full Text] [Related]
11. Cancer induction in mice by 4-hydroxybenzenediazonium sulfate of the Agaricus xanthodermus mushroom.
Toth B; Patil K; Taylor J; Stessman C; Gannett P
In Vivo; 1989; 3(5):301-5. PubMed ID: 2519869
[TBL] [Abstract][Full Text] [Related]
12. Cells with loss-of-heterozygosity after exposure to ionizing radiation in Drosophila are culled by p53-dependent and p53-independent mechanisms.
Brown J; Bush I; Bozon J; Su TT
PLoS Genet; 2020 Oct; 16(10):e1009056. PubMed ID: 33075096
[TBL] [Abstract][Full Text] [Related]
13. [Susceptibility of wild and knockout p53 FVB/N line mice to benz(a)pyrene-induced subcutaneous sarcoma].
Anikin IV; Kozlov AP; Popov AV; Zabezhinskiĭ MA; Tyndyk ML; Anisimov VN
Vopr Onkol; 2002; 48(6):700-2. PubMed ID: 12530267
[TBL] [Abstract][Full Text] [Related]
14. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
15. Induction of transplantable tumors by repeated subcutaneous injections of natural and synthetic vitamin E in mice and rats.
Nitta Y; Kamiya K; Tanimoto M; Sadamoto S; Niwa O; Yokoro K
Jpn J Cancer Res; 1991 May; 82(5):511-7. PubMed ID: 1905698
[TBL] [Abstract][Full Text] [Related]
16. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.
Schneider-Stock R; Boltze C; Peters B; Szibor R; Landt O; Meyer F; Roessner A
Neoplasia; 2004; 6(5):529-35. PubMed ID: 15548361
[TBL] [Abstract][Full Text] [Related]
17. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
Honma M
Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
[TBL] [Abstract][Full Text] [Related]
18. Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate as used in cosmetics.
Elmore AR
Int J Toxicol; 2005; 24 Suppl 2():51-111. PubMed ID: 16154915
[TBL] [Abstract][Full Text] [Related]
19. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice.
Dunnick JK; Hardisty JF; Herbert RA; Seely JC; Furedi-Machacek EM; Foley JF; Lacks GD; Stasiewicz S; French JE
Toxicol Pathol; 1997; 25(6):533-40. PubMed ID: 9437796
[TBL] [Abstract][Full Text] [Related]
20. Induction of soft tissue tumours in F344 rats by subcutaneous, intramuscular, intra-articular, and retroperitoneal injection of nickel sulphide (Ni3S2).
Shibata M; Izumi K; Sano N; Akagi A; Otsuka H
J Pathol; 1989 Mar; 157(3):263-74. PubMed ID: 2538612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
